secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001193125-24-211572
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports positive Phase 1/2 data for VAX-31; all serotypes meet immunogenicity criteria
--------------------------------------------------------------------------------

- VAX-31 showed robust OPA responses for all 31 serotypes at all doses; safety profile similar to Prevnar20.
- At high and middle doses, VAX-31 met or exceeded non-inferiority criteria for all 20 serotypes common with PCV20.
- For 11 unique serotypes, all three doses met superiority criteria.
- Company selects VAX-31 for adult Phase 3; plans to initiate pivotal study by mid-2025 with topline data in 2026.
- Also plans VAX-31 infant Phase 2 study in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312524211572/0001193125-24-211572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312524211572/d813919d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-211572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer